Second Department of Urology, Centre of Postgraduate Medical Education, 02-511 Warsaw, Poland.
Department of Nuclear Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Curr Oncol. 2024 Jul 24;31(8):4165-4177. doi: 10.3390/curroncol31080311.
Prostate cancer represents a significant public health challenge, with its management requiring precise diagnostic and prognostic tools. Prostate-specific membrane antigen (PSMA), a cell surface enzyme overexpressed in prostate cancer cells, has emerged as a pivotal biomarker. PSMA's ability to increase the sensitivity of PET imaging has revolutionized its application in the clinical management of prostate cancer. The advancements in PET-PSMA imaging technologies and methodologies, including the development of PSMA-targeted radiotracers and optimized imaging protocols, led to diagnostic accuracy and clinical utility across different stages of prostate cancer. This highlights its superiority in staging and its comparative effectiveness against conventional imaging modalities. This paper analyzes the impact of PET-PSMA on prostate cancer management, discussing the existing challenges and suggesting future research directions. The integration of recent studies and reviews underscores the evolving understanding of PET-PSMA imaging, marking its significant but still expanding role in clinical practice. This comprehensive review serves as a crucial resource for clinicians and researchers involved in the multifaceted domains of prostate cancer diagnosis, treatment, and management.
前列腺癌是一个重大的公共健康挑战，其管理需要精确的诊断和预后工具。前列腺特异性膜抗原（PSMA）是一种在前列腺癌细胞中过度表达的细胞表面酶，已成为一个关键的生物标志物。PSMA 提高 PET 成像灵敏度的能力使其在前列腺癌的临床管理中得到了革命性的应用。PET-PSMA 成像技术和方法的进步，包括 PSMA 靶向放射性示踪剂的开发和优化的成像方案，提高了不同阶段前列腺癌的诊断准确性和临床实用性。这凸显了它在分期方面的优势，以及与传统成像方式相比的比较有效性。本文分析了 PET-PSMA 对前列腺癌管理的影响，讨论了现有的挑战，并提出了未来的研究方向。最近的研究和综述的整合强调了对 PET-PSMA 成像的不断发展的理解，标志着它在临床实践中的重要但仍在扩大的作用。这篇全面的综述为参与前列腺癌诊断、治疗和管理各个方面的临床医生和研究人员提供了一个至关重要的资源。
